Two wrongful death lawsuits were recently commenced on behalf of individuals who lost their lives due to their use of the blood-thinning drug Xarelto.  Both cases allege that Xarelto is falsely advertised as a “one size fits all” for patients and does not indicate on the bottle that there exists no available reversal agent to stop bleeding once it begins. 

Both of the plaintiffs in these cases started taking Xarelto and shortly thereafter developed bleeding in the brain.  When hospital doctors attempted to stop it, there were no remedies that could combat the Xarelto induced bleeding.  For the more well known drug that is used to control blood clotting, Coumadin (warfarin), the regular procedures that doctors use usually work.

One of the plaintiffs, Graham Padrick, age 76, was switched to Xarelto from Coumadin to treat atrial fibrillation in January of 2013.  Within a month he developed a subdural hematoma and died on February 14, 2013.  He left a widow and three children.

The other plaintiff, Ladson Romano, age 67, was put on Xarelto in November of 2014 because he had the potential to develop deep vein thrombosis.  Within a month he developed hemorrhaging in his brain stem and ultimately died on December 20, 2014.   

The claims in both of these cases assert liability for the lack of a reversal agent and the promotion of Xarelto as a blood thinner that does not require frequent patient monitoring.  Furthermore, they assert that the daily dose of Xarelto, which is not tailored to the need of individual patients, is negligent because of differences in age, weight and liver function of individual patients.  

The families of these two victims deserve compensation in a court of law for their losses.